Chardan Capital Initiates Coverage On iBio with Buy Rating, Announces Price Target of $5
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has initiated coverage on iBio (AMEX:IBIO) with a Buy rating and set a price target of $5.
May 28, 2024 | 10:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has initiated coverage on iBio with a Buy rating and set a price target of $5. This positive analyst rating could boost investor confidence and potentially drive the stock price up in the short term.
The initiation of coverage with a Buy rating and a specific price target of $5 by Chardan Capital is a strong positive signal. Such analyst actions often lead to increased investor interest and buying activity, which can drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100